Develops oral formulations of drugs and biologics, leveraging its proprietary drug delivery platform to improve treatment outcomes.
Entera Bio Ltd., a clinical-stage biopharmaceutical firm, specializes in advancing and commercializing orally delivered large molecule therapeutics to address significant medical needs.
Leading its portfolio are EB612 and EB613. EB612 is currently in Phase II clinical trials for hypoparathyroidism, while EB613 has completed Phase II trials for osteoporosis and is in Phase I trials for non-union fractures treatment. Additionally, Entera Bio has forged a strategic research collaboration and license agreement with Amgen Inc., focusing on developing clinical candidates targeting inflammatory diseases and other critical conditions.
Founded in 2009 and headquartered in Jerusalem, Israel, Entera Bio Ltd. continues to innovate at the forefront of oral biologic drug delivery. The company's commitment to pioneering advancements in therapeutic solutions underscores its mission to improve patient outcomes globally.